In 2021, Lumira Ventures and Angelini Pharma launched the Angelini Lumira Biosciences Fund (ALBF) to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. Through our collective knowledge, experience and passion, we are laser-focused on identifying transformative discoveries with the potential to improve patients living with CNS diseases, including neuropsychiatric indications.
Since its launch, the Fund has made four investments to support innovative CNS-focused companies, and today, on World Mental Health Day, we would like to shine a spotlight on our most recent investment, DAMONA Pharmaceuticals, a company dedicated to creating a new class of therapies for patients living with cognitive deficits associated with depression. By funding innovative research in neuropsychiatry, we are contributing towards the ongoing efforts in finding novel therapies for patients suffering from mental illnesses. Estimates suggest a >25% rise in depressive disorders and a widening treatment gap for mental health illness, especially since the pandemic. Through our growing efforts, we hope to stimulate deeper conversations and greater understanding, while continuing to support new treatments with a promise to improve patient care for mental disorders at a global scale.